Epstein Files Full PDF

CLICK HERE
Technopedia Center
PMB University Brochure
Faculty of Engineering and Computer Science
S1 Informatics S1 Information Systems S1 Information Technology S1 Computer Engineering S1 Electrical Engineering S1 Civil Engineering

faculty of Economics and Business
S1 Management S1 Accountancy

Faculty of Letters and Educational Sciences
S1 English literature S1 English language education S1 Mathematics education S1 Sports Education
teknopedia

  • Registerasi
  • Brosur UTI
  • Kip Scholarship Information
  • Performance
Flag Counter
  1. World Encyclopedia
  2. Utidelone - Wikipedia
Utidelone - Wikipedia
From Wikipedia, the free encyclopedia
Drug for treatment of breast cancer

Pharmaceutical compound
Utidelone
Clinical data
Trade names優替帝
Other namesEpothilone D; desoxyepothilone B
ATC code
  • L01DC05 (WHO)
Legal status
Legal status
  • Rx in China
Identifiers
CAS Number
  • 189453-10-9
PubChem CID
  • 447865
DrugBank
  • DB17575
UNII
  • T0358E0YUF
CompTox Dashboard (EPA)
  • DTXSID70880053 Edit this at Wikidata
Chemical and physical data
FormulaC27H41NO5S
Molar mass491.69 g·mol−1

Utidelone is a pharmaceutical drug for the treatment of metastatic breast cancer. It was approved for use in China in 2021.[1][2]

Utidelone is a member of the epothilone class of natural products, which are metabolites produced by the soil-dwelling myxobacterium Sorangium cellulosum.[3] It is also known as epothilone D.

References

[edit]
  1. ^ "New Drug Approvals in China in 2021". diaglobal.org. 2 May 2022.
  2. ^ Villegas C, González-Chavarría I, Burgos V, Iturra-Beiza H, Ulrich H, Paz C (March 2023). "Epothilones as Natural Compounds for Novel Anticancer Drugs Development". International Journal of Molecular Sciences. 24 (7): 6063. doi:10.3390/ijms24076063. PMC 10093981. PMID 37047035.
  3. ^ Avendaño C, Menéndez JC (2023). "Anticancer drugs targeting tubulin and microtubules". Medicinal Chemistry of Anticancer Drugs: 445–491. doi:10.1016/B978-0-12-818549-0.00017-0. ISBN 978-0-12-818549-0.
  • v
  • t
  • e
Intracellular chemotherapeutic agents / antineoplastic agents (L01)
SPs/MIs
(M phase)
Block microtubule assembly
  • Vinca alkaloids (Vinblastine#
  • Vincristine#
  • Vindesine
  • Vinflunine§
  • Vinorelbine#)
Block microtubule disassembly
  • Taxanes (Cabazitaxel
  • Docetaxel#
  • Larotaxel
  • Ortataxel†
  • Paclitaxel#
  • Tesetaxel)
  • Epothilones (Ixabepilone)
DNA replication
inhibitor
DNA precursors/
antimetabolites
(S phase)
Folic acid
  • Dihydrofolate reductase inhibitor (Aminopterin
  • Methotrexate#
  • Pemetrexed
  • Pralatrexate)
  • Thymidylate synthase inhibitor (Pemetrexed
  • Raltitrexed)
Purine
  • Adenosine deaminase inhibitor (Pentostatin)
  • Halogenated/ribonucleotide reductase inhibitors (Cladribine#
  • Clofarabine
  • Fludarabine#)
  • Nelarabine
  • Rabacfosadine
  • Thiopurine (Mercaptopurine#
  • Tioguanine#)
Pyrimidine
  • Thymidylate synthase inhibitor (Capecitabine#
  • Carmofur
  • Doxifluridine
  • Floxuridine
  • Fluorouracil#
  • Tegafur (+gimeracil/oteracil))
  • DNA polymerase inhibitor (Cytarabine# +daunorubicin)
  • Ribonucleotide reductase inhibitor (Gemcitabine#)
  • Hypomethylating agent (Azacitidine
  • Decitabine)
Deoxyribonucleotide
  • Ribonucleotide reductase inhibitor (Hydroxycarbamide#)
Topoisomerase inhibitors
(S phase)
I
  • Camptotheca (Belotecan
  • Camptothecin
  • Cositecan†
  • Etirinotecan pegol†
  • Exatecan
  • Gimatecan
  • Irinotecan#
  • Lurtotecan‡
  • Rubitecan‡
  • Silatecan§
  • Topotecan)
II
  • Podophyllum (Etoposide#
  • Teniposide)
II+Intercalation
  • Anthracyclines (Aclarubicin
  • Amrubicin†
  • Daunorubicin# (+cytarabine)
  • Doxorubicin#
  • Epirubicin
  • Idarubicin
  • Pirarubicin
  • Valrubicin
  • Zorubicin)
  • Anthracenediones (Losoxantrone
  • Mitoxantrone
  • Pixantrone)
  • Amsacrine
  • Bisantrene
  • Crisnatol
  • Menogaril§
Crosslinking of DNA
(CCNS)
Alkylating
  • Nitrogen mustards: Bendamustine#
  • Chlormethine
  • Cyclophosphamide# (Ifosfamide#
  • Trofosfamide)
  • Chlorambucil#
  • Melphalan (Melphalan flufenamide)
  • Prednimustine
  • Uramustine
  • Nitrosoureas: Carmustine
  • Fotemustine
  • Lomustine (Semustine)
  • Nimustine
  • Ranimustine
  • Streptozocin
  • Alkyl sulfonates: Busulfan (Mannosulfan
  • Treosulfan)
  • Aziridines: Carboquone
  • Thiotepa
  • Triaziquone
  • Triethylenemelamine
Platinum-based
  • Carboplatin#
  • Cisplatin#
  • Dicycloplatin
  • Nedaplatin
  • Oxaliplatin#
  • Satraplatin
Nonclassical
  • Altretamine
  • Hydrazines (Procarbazine#)
  • Etoglucid
  • Mitobronitol
  • Pipobroman
  • Triazenes (Dacarbazine#
  • Mitozolomide§
  • Temozolomide)
Intercalation
  • Streptomyces (Dactinomycin#
  • Bleomycin# (Pingyangmycin)
  • Ixabepilone
  • Mitomycin
  • Plicamycin
  • Utidelone)
Photosensitizers/PDT
  • Aminolevulinic acid
  • Efaproxiral
  • Methyl aminolevulinate
  • Padeliporfin
  • Porphyrin derivatives (Porfimer sodium
  • Talaporfin
  • Temoporfin
  • Verteporfin)
Other
Enzyme inhibitors
  • FI (Tipifarnib§)
  • CDK inhibitors (Abemaciclib
  • Alvocidib†
  • Palbociclib
  • Ribociclib
  • Seliciclib†)
  • PrI
    • Bortezomib#
    • Carfilzomib
    • Oprozomib
    • Ixazomib
  • PhI (Anagrelide)
  • IMPDI (Tiazofurin§)
  • LI (Masoprocol)
  • PARP inhibitor (Fuzuloparib
  • Niraparib +abiraterone acetate
  • Olaparib
  • Rucaparib)
  • HDAC (Belinostat
  • Entinostat
  • Panobinostat
  • Romidepsin
  • Vorinostat)
  • PIKI (Pi3K) (Alpelisib
  • Copanlisib‡
  • Duvelisib
  • Idelalisib
  • Inavolisib
  • Umbralisib‡)
  • IDH (Enasidenib
  • Ivosidenib
  • Olutasidenib
  • Vorasidenib)
Receptor antagonists
  • ERA (Atrasentan)
  • Retinoid X receptor (Bexarotene)
  • Sex steroid (Testolactone)
Other/ungrouped
  • Adagrasib
  • Aflibercept
  • Arsenic trioxide# (Realgar/Indigo naturalis#)
  • Asparagine depleters (Asparaginase#/Pegaspargase)
  • Axicabtagene ciloleucel
  • Belzutifan
  • Bexarotene
  • Brexucabtagene autoleucel
  • Calaspargase pegol
  • Celecoxib
  • Ciltacabtagene autoleucel
  • Darinaparsin
  • Demecolcine
  • Denileukin diftitox
  • Eflornithine
  • Elesclomol§
  • Elsamitrucin
  • Epacadostat
  • Eribulin
  • Estramustine
  • Glasdegib
  • Idecabtagene vicleucel
  • Idroxioleic acid
  • Imetelstat
  • Lifileucel
  • Lisocabtagene maraleucel
  • Lonidamine
  • Lucanthone
  • Lurbinectedin
  • Mitoguazone
  • Mitotane
  • Nadofaragene firadenovec
  • Navitoclax
  • Nirogacestat
  • Obecabtagene autoleucel
  • Oblimersen†
  • Omacetaxine mepesuccinate
  • Para-toluenesulfonamide
  • Pelabresib
  • Plitidepsin
  • Retinoids (Alitretinoin
  • Tretinoin#)
  • Selinexor
  • Sitimagene ceradenovec
  • Sotorasib
  • Tabelecleucel
  • Tagraxofusp
  • Talimogene laherparepvec
  • Tazemetostat
  • Tebentafusp
  • Tiazofurine
  • Tigilanol tiglate
  • Tisagenlecleucel
  • Trabectedin
  • Veliparib
  • Venetoclax
  • Verdinexor
  • Vosaroxin
  • #WHO-EM
  • ‡Withdrawn from market
  • Clinical trials:
    • †Phase III
    • §Never to phase III


Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by adding missing information.

  • v
  • t
  • e
Retrieved from "https://teknopedia.ac.id/w/index.php?title=Utidelone&oldid=1330637908"
Categories:
  • Antineoplastic and immunomodulating drugs
  • Antineoplastic and immunomodulating drug stubs
Hidden categories:
  • Articles with short description
  • Short description is different from Wikidata
  • Drugs with non-standard legal status
  • Articles without EBI source
  • Chemical pages without ChemSpiderID
  • Articles without KEGG source
  • Articles without InChI source
  • Articles containing unverified chemical infoboxes
  • All stub articles

  • indonesia
  • Polski
  • العربية
  • Deutsch
  • English
  • Español
  • Français
  • Italiano
  • مصرى
  • Nederlands
  • 日本語
  • Português
  • Sinugboanong Binisaya
  • Svenska
  • Українська
  • Tiếng Việt
  • Winaray
  • 中文
  • Русский
Sunting pranala
url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url
Pusat Layanan

UNIVERSITAS TEKNOKRAT INDONESIA | ASEAN's Best Private University
Jl. ZA. Pagar Alam No.9 -11, Labuhan Ratu, Kec. Kedaton, Kota Bandar Lampung, Lampung 35132
Phone: (0721) 702022
Email: pmb@teknokrat.ac.id